

Adoport® 2mg capsules – Shortage/Out of stock

This information has been produced by the NHS Grampian Medicines Management department in collaboration with Renal specialist service.

Shortage information

A shortage of Adoport® 2mg capsules (tacrolimus immediate release) has been identified. A resupply date has not been provided. Other strengths are not impacted at this time. This is based on company information received from Sandoz on 18th July 2023.

Prescribing in NHS Grampian

57 patients have been identified as being prescribing Adoport® 2mg capsules within NHS Grampian. Adoport® is primarily used in renal patients to prevent rejection following transplant.

Stock information & availability

- Adoport® must be prescribing by brand
- Adoport® 1mg capsules remain in stock - the company state that 2 x 1mg Adoport® capsules can be used where 2mg Adoport® capsules are not available.
- There are sufficient supplies of Adoport® 1mg to cover this change.

Formulary status

Adoport® is recognised brand of tacrolimus utilised by renal specialists in NHS Grampian.

Actions for primary care

It is vital the patient receives a consistent supply of the Adoport® brand of tacrolimus. To ensure maintenance of therapeutic response different brands should not be interchanged and Adoport® should be prescribed by brand name.

Due to the nature of this medicines and the need for ongoing treatment it is recommended that the following proactive actions are taken:

- Review when patients last received a supply and check when they will next require a prescription/supply.
- Liaise with community pharmacy to determine, any current stocks and also if they are able to obtain Adoport® 2mg capsules, or if unavailable Adoport® 1mg capsules
- Supply prescriptions accordingly
- Ensure patients/carers are made aware if they are receiving an alternative strength of capsules
- No new patients should be initiated on this 2mg strength whilst this shortage is active.

Actions for Community Pharmacy

It is vital the patient receives a consistent supply of the Adoport® brand of tacrolimus. To ensure maintenance of therapeutic response different brands should not be interchanged and Adoport® should be prescribed by brand name.

- Liaise with GP practice/patients to identify patients that will require supplies
- Determine availability of Adoport® 2mg and 1mg capsules – checking in regularly with all wholesalers
- If Adoport® 1mg capsules are to be supplied ensure the patient/carer is counselled about the shortage, and the need to supply a different strength. Ensure they are clear regarding the dose/number of capsules to be taken.
- Continue to review supply of 2mg capsules and liaise accordingly with practices, ensuring patients are informed of any further changes in strength of product prescribed.

Data information

Data provided is ePrescribed April- July 2023

The data provides prescribing information. It does not confirm that the prescription has been dispensed by community pharmacy or collected by the patient.

The data only captures electronic prescribing information – any handwritten prescriptions will not be included.

Duplicate CHI have been removed for ease of use.